Results from a pioneer study showed that combining anti-CD33 CAR-DC with anti-CD33 CAR-T cells enhanced CAR-T cell function and cytotoxicity compared to the results obtained with CAR-T cells alone, resulting in improved tumor control in AML xenograft mouse models 75. This evidence concerns the gene CD33 and acute myeloid leukemia.